Mizuho Securities Reiterates Buy Rating, $57 Price Target on Arcutis Biotherapeutics (AQRT), Cites INCY's Opzelura's High Pace of Adoption
Tweet Send to a Friend
Mizuho Securities analyst Uy Ear reiterated a Buy rating and $57.00 price target on Arcutis Biotherapeutics (NASDAQ: AQRT), following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
